{"entity":{"type":"insider","cik":"0001616165","url":"/insider/0001616165","json_url":"/insider/0001616165.json","name":"ARCH Venture Partners VIII, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":12,"n_filings":8,"first":"2017-12-13","last":"2025-10-29","span_basis":"filed_date"},"name_variants":[{"name":"ARCH Venture Partners VIII, LLC","source":"filing","n_filings":8,"first_seen":"2017-12-13","last_seen":"2025-10-29"}],"transactions":[{"id":5119195,"accession":"0001012975-25-000679","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-25-000679","line_url":"/filing/0001012975-25-000679#line-1","is_derivative":false,"issuer_cik":"0001402439","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001402439","owner_cik":null,"owner_name":"ARCH Venture Fund X, L.P.; ARCH Venture Fund VII, L.P.; ARCH Venture Partners X, L.P.; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners X, LLC; ARCH Venture Partners VII, L.P.; ARCH Venture Fund VIII Overage, L.P.; ARCH Venture Fund X Overage, L.P.; ARCH Venture Partners VII, LLC; ARCH Venture Partners VIII, LLC","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1915700.0,"shares_display":"1,915,700","price_per_share":2.61,"price_display":"2.61","price_state":"stated","total_value":4999977.0,"total_display":"4,999,977.00","shares_owned_after":6046907.0,"shares_owned_after_display":"6,046,907","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-27","filed_date":"2025-10-29","scope":"insider"},{"id":7915440,"accession":"0000899243-23-019273","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-23-019273","line_url":"/filing/0000899243-23-019273#line-6","is_derivative":false,"issuer_cik":"0001402439","issuer_name":"Neumora Therapeutics, Inc.","issuer_ticker":"NMRA","issuer_name_source":null,"issuer_url":"/issuer/0001402439","owner_cik":null,"owner_name":"ARCH Venture Fund VII, L.P.; ARCH Venture Fund X, L.P.; ARCH Venture Partners VII, LLC; ARCH Venture Partners X, L.P.; ARCH Venture Partners X, LLC; ARCH Venture Partners X Overage, L.P.; ARCH Venture Partners VII, L.P.; ARCH Venture Partners VIII, LLC; ARCH Venture Fund VIII Overage, L.P.; ARCH Venture Fund X Overage, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1500000.0,"shares_display":"1,500,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":25500000.0,"total_display":"25,500,000.00","shares_owned_after":3624143.0,"shares_owned_after_display":"3,624,143","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-19","filed_date":"2023-09-20","scope":"insider"},{"id":6629465,"accession":"0001062993-22-019586","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001062993-22-019586","line_url":"/filing/0001062993-22-019586#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Codiak BioSciences, Inc.","issuer_ticker":"CDAK","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"ARCH Venture Partners VIII, LLC; ARCH Venture Partners VIII, L.P.; NELSEN ROBERT; ARCH Venture Fund VIII, L.P.; ARCH Venture Fund VIII Overage, L.P.; CRANDELL KEITH; BYBEE CLINTON","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Sotck","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000000.0,"shares_display":"5,000,000","price_per_share":1.5,"price_display":"1.50","price_state":"stated","total_value":7500000.0,"total_display":"7,500,000.00","shares_owned_after":8854098.0,"shares_owned_after_display":"8,854,098","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-13","filed_date":"2022-09-15","scope":"insider"},{"id":2066735,"accession":"0000899243-20-028809","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0000899243-20-028809","line_url":"/filing/0000899243-20-028809#line-6","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Codiak BioSciences, Inc.","issuer_ticker":"CDAK","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"CRANDELL KEITH; ARCH Venture Fund VIII, L.P.; BYBEE CLINTON; ARCH Venture Fund VIII Overage, L.P.; NELSEN ROBERT; ARCH Venture Partners VIII, LLC; ARCH Venture Partners VIII, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":235000.0,"shares_display":"235,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":3525000.0,"total_display":"3,525,000.00","shares_owned_after":2503903.0,"shares_owned_after_display":"2,503,903","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-16","filed_date":"2020-10-20","scope":"insider"},{"id":2657738,"accession":"0001209191-20-051402","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-20-051402","line_url":"/filing/0001209191-20-051402#line-6","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"NELSEN ROBERT; ARCH Venture Partners VIII, LLC; ARCH Venture Partners VIII, L.P.; ARCH Venture Fund VIII, L.P.; BYBEE CLINTON; CRANDELL KEITH; ARCH Venture Fund VIII Overage, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":210000.0,"shares_display":"210,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":2730000.0,"total_display":"2,730,000.00","shares_owned_after":2781769.0,"shares_owned_after_display":"2,781,769","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-09-18","filed_date":"2020-09-22","scope":"insider"},{"id":2657735,"accession":"0001209191-20-051402","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-20-051402","line_url":"/filing/0001209191-20-051402#line-5","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Metacrine, Inc.","issuer_ticker":"MTCR","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"NELSEN ROBERT; ARCH Venture Partners VIII, LLC; ARCH Venture Partners VIII, L.P.; ARCH Venture Fund VIII, L.P.; BYBEE CLINTON; CRANDELL KEITH; ARCH Venture Fund VIII Overage, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":13.0,"price_display":"13.00","price_state":"stated","total_value":260000.0,"total_display":"260,000.00","shares_owned_after":158734.0,"shares_owned_after_display":"158,734","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-09-18","filed_date":"2020-09-22","scope":"insider"},{"id":8199732,"accession":"0001012975-19-000198","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001012975-19-000198","line_url":"/filing/0001012975-19-000198#line-3","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Sienna Biopharmaceuticals, Inc.","issuer_ticker":"SNNA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"CRANDELL KEITH; NELSEN ROBERT; BYBEE CLINTON; ARCH Venture Fund VIII Overage, L.P.; ARCH Venture Fund VIII, L.P.; ARCH Venture Partners VIII, LLC; ARCH Venture Partners VIII, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1865800.0,"shares_display":"1,865,800","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":4664500.0,"total_display":"4,664,500.00","shares_owned_after":1865800.0,"shares_owned_after_display":"1,865,800","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-22","filed_date":"2019-02-26","scope":"insider"},{"id":8199730,"accession":"0001012975-19-000198","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001012975-19-000198","line_url":"/filing/0001012975-19-000198#line-2","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Sienna Biopharmaceuticals, Inc.","issuer_ticker":"SNNA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"CRANDELL KEITH; NELSEN ROBERT; BYBEE CLINTON; ARCH Venture Fund VIII Overage, L.P.; ARCH Venture Fund VIII, L.P.; ARCH Venture Partners VIII, LLC; ARCH Venture Partners VIII, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":375000.0,"total_display":"375,000.00","shares_owned_after":2900575.0,"shares_owned_after_display":"2,900,575","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-22","filed_date":"2019-02-26","scope":"insider"},{"id":8199726,"accession":"0001012975-19-000198","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001012975-19-000198","line_url":"/filing/0001012975-19-000198#line-1","is_derivative":false,"issuer_cik":"0001219039","issuer_name":"Sienna Biopharmaceuticals, Inc.","issuer_ticker":"SNNA","issuer_name_source":null,"issuer_url":"/issuer/0001219039","owner_cik":null,"owner_name":"CRANDELL KEITH; NELSEN ROBERT; BYBEE CLINTON; ARCH Venture Fund VIII Overage, L.P.; ARCH Venture Fund VIII, L.P.; ARCH Venture Partners VIII, LLC; ARCH Venture Partners VIII, L.P.","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":150000.0,"shares_display":"150,000","price_per_share":2.5,"price_display":"2.50","price_state":"stated","total_value":375000.0,"total_display":"375,000.00","shares_owned_after":1032493.0,"shares_owned_after_display":"1,032,493","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-02-22","filed_date":"2019-02-26","scope":"insider"},{"id":6040042,"accession":"0001012975-18-001198","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001012975-18-001198","line_url":"/filing/0001012975-18-001198#line-7","is_derivative":false,"issuer_cik":"0001219042","issuer_name":"Twist Bioscience Corp","issuer_ticker":"TWST","issuer_name_source":null,"issuer_url":"/issuer/0001219042","owner_cik":null,"owner_name":"ARCH Venture Partners VII, LLC; ARCH Venture Partners VII, L.P.; ARCH Venture Partners VIII, LLC; ARCH Venture Fund VIII Overage, L.P.; BYBEE CLINTON; ARCH Venture Fund VII, L.P.; NELSEN ROBERT","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60000.0,"shares_display":"60,000","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":840000.0,"total_display":"840,000.00","shares_owned_after":954146.0,"shares_owned_after_display":"954,146","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-11-02","filed_date":"2018-11-06","scope":"insider"},{"id":6040039,"accession":"0001012975-18-001198","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001012975-18-001198","line_url":"/filing/0001012975-18-001198#line-6","is_derivative":false,"issuer_cik":"0001219042","issuer_name":"Twist Bioscience Corp","issuer_ticker":"TWST","issuer_name_source":null,"issuer_url":"/issuer/0001219042","owner_cik":null,"owner_name":"ARCH Venture Partners VII, LLC; ARCH Venture Partners VII, L.P.; ARCH Venture Partners VIII, LLC; ARCH Venture Fund VIII Overage, L.P.; BYBEE CLINTON; ARCH Venture Fund VII, L.P.; NELSEN ROBERT","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":15000.0,"shares_display":"15,000","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":210000.0,"total_display":"210,000.00","shares_owned_after":2407422.0,"shares_owned_after_display":"2,407,422","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-11-02","filed_date":"2018-11-06","scope":"insider"},{"id":5350142,"accession":"0001104659-17-073156","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001104659-17-073156","line_url":"/filing/0001104659-17-073156#line-7","is_derivative":false,"issuer_cik":"0001219042","issuer_name":"Quanterix Corp","issuer_ticker":"QTRX","issuer_name_source":null,"issuer_url":"/issuer/0001219042","owner_cik":null,"owner_name":"ARCH Venture Fund VIII Overage, L.P.; BYBEE CLINTON; ARCH VENTURE PARTNERS VI LP; ARCH VENTURE PARTNERS VI LLC; ARCH Venture Partners VIII, LLC; ARCH VENTURE FUND VI LP; NELSEN ROBERT","owner_url":null,"role":"Ten percent owner","officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":266000.0,"shares_display":"266,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":3990000.0,"total_display":"3,990,000.00","shares_owned_after":1537684.0,"shares_owned_after_display":"1,537,684","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-11","filed_date":"2017-12-13","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001885522","name":"Neumora Therapeutics, Inc.","url":"/issuer/0001885522","role":"Ten percent owner","n_filings":2,"first_seen":"2023-09-20","last_seen":"2025-10-29"},{"type":"issuer","type_label":"ISSUER","cik":"0001659352","name":"Codiak BioSciences, Inc.","url":"/issuer/0001659352","role":"Ten percent owner","n_filings":2,"first_seen":"2020-10-20","last_seen":"2022-09-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001634379","name":"Metacrine, Inc.","url":"/issuer/0001634379","role":"Ten percent owner","n_filings":1,"first_seen":"2020-09-22","last_seen":"2020-09-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001656328","name":"Sienna Biopharmaceuticals, Inc.","url":"/issuer/0001656328","role":"Ten percent owner","n_filings":1,"first_seen":"2019-02-26","last_seen":"2019-02-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001581280","name":"Twist Bioscience Corp","url":"/issuer/0001581280","role":"Ten percent owner","n_filings":1,"first_seen":"2018-11-06","last_seen":"2018-11-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001503274","name":"Quanterix Corp","url":"/issuer/0001503274","role":"Ten percent owner","n_filings":1,"first_seen":"2017-12-13","last_seen":"2017-12-13"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001616165","retrieved_at":"2026-08-20T18:42:48+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-19","last_ingest":"2026-08-20T05:22:56.381658+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}